Literature DB >> 26754930

Inflammatory markers in patients with obstructive sleep apnea.

Tomoyuki Kawada1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26754930     DOI： 10.1007/s11325-015-1302-z

Source DB:  PubMed          Journal:  Sleep Breath        ISSN： 1520-9512            Impact factor:   2.816


× No keyword cloud information.
  6 in total

1.  Erythrocyte sedimentation rate may help predict severity of obstructive sleep apnea.

Authors:  Woo Hyun Lee; Jee Hye Wee; Chae-Seo Rhee; In-Young Yoon; Jeong-Whun Kim
Journal:  Sleep Breath       Date:  2015-08-28       Impact factor: 2.816

2.  Association between components of the metabolic syndrome and serum levels of C-reactive protein in Japanese workingmen.

Authors:  Tomoyuki Kawada; Toshiaki Otsuka; Masao Katsumata; Hiroko Suzuki
Journal:  J Cardiometab Syndr       Date:  2006

3.  The impact of obstructive sleep apnea on high-sensitivity C-reactive protein in subjects with or without metabolic syndrome.

Authors:  Wei-Te Wu; Su-Shan Tsai; Tung-Sheng Shih; Ming-Hsiu Lin; Tzu-Chieh Chou; Hua Ting; Trong-Neng Wu; Saou-Hsing Liou
Journal:  Sleep Breath       Date:  2015-04-07       Impact factor: 2.816

4.  C-reactive protein and myocardial infarction.

Authors:  Pamela Sakkinen; Robert D Abbott; J David Curb; Beatriz L Rodriguez; Katsuhiko Yano; Russell P Tracy
Journal:  J Clin Epidemiol       Date:  2002-05       Impact factor: 6.437

5.  Obstructive sleep apnea is independently associated with inflammation and insulin resistance, but not with blood pressure, plasma catecholamines, and endothelial function in obese subjects.

Authors:  Luciene da Silva Araújo; Julia Freitas Rodrigues Fernandes; Márcia Regina Simas Torres Klein; Antonio Felipe Sanjuliani
Journal:  Nutrition       Date:  2015-06-20       Impact factor: 4.008

6.  Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans.

Authors:  Shuhei Nakanishi; Kiminori Yamane; Nozomu Kamei; Masamichi Okubo; Nobuoki Kohno
Journal:  Diabetes Care       Date:  2003-10       Impact factor: 19.112
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.